Streetbeat News

Products Services

GM

General Motors' robo-taxi unit Cruise has enlisted an independent law firm and tech consultants to review its operations following a collision that led to a temporary halt of its self-driving car operations. The company's permit for operating driverless cars was revoked by California authorities due to safety concerns. Despite recent setbacks, GM CEO Mary Barra projects that Cruise could bring in revenues of $50 billion by 2030.

Portfolio Pulse from Nabaparna Bhattacharya

November 04, 2023 | 7:34 pm

DIS

DKNG

MGM

PENN

The past week saw significant developments in the sports betting industry, including the Texas Rangers winning the World Series, the first NCAA Playoff rankings, and the trade of NBA star James Harden. DraftKings Inc (NASDAQ:DKNG) reported a 57% YoY increase in Q3 revenue to $790 million, beating estimates, and raised its guidance for 2023 and 2024. PENN Entertainment (NASDAQ:PENN) announced the launch of its ESPN Bet platform on Nov. 14, initially available in 17 states. BetMGM, a joint venture between MGM Resorts International (NYSE:MGM) and Entain, saw improved betting odds on NBA rookie Victor Wembanyama.

Portfolio Pulse from Chris Katje

November 03, 2023 | 9:18 pm

SGAMY

SEGA executive Osamu Ohasi has expressed his ambition for Sonic the Hedgehog to surpass Mario in terms of popularity. Ohasi, who manages SEGA's 2nd Business Department responsible for the Sonic franchise, wants Sonic to be played globally and the Sonic movie to be a bigger hit than Mario. However, achieving these objectives will be challenging as the recent Super Mario Bros. movie grossed $1.36 billion at the box office, while the two Sonic movies combined generated a total of $725 million. In terms of video game sales, Mario is the best-selling video game franchise of all time, with over 830 million copies sold globally.

Portfolio Pulse from Franca Quarneti

November 03, 2023 | 8:53 pm

ALGS

Aligos Therapeutics, Inc. (NASDAQ:ALGS) will host a virtual KOL event to review the Late Breaking results and next steps for ALG-000184, its Phase 1 CAM-E drug candidate for chronic Hepatitis B (CHB). The event will feature Mark Sulkowski, MD, Professor of Medicine at the Johns Hopkins University School of Medicine, and will take place on November 16, 2023. The Phase 1 data are being featured in a late breaking poster session at the Liver Meeting® of the American Association of Liver Disease on November 13, 2023.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 8:32 pm

ELTX

Elicio Therapeutics (NASDAQ:ELTX) has presented updated preliminary data from its ongoing Phase 1 study of ELI-002, a therapeutic cancer vaccine, and new preclinical data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer Annual Meeting. The data shows promising results in patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers. The strength of the induced T cell response correlated with a significantly reduced risk of relapse and death. ELI-007 and ELI-008 also demonstrated strong induction of tumor-antigen-specific T cell responses in mice.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 8:31 pm

PFE

SGMO

Sangamo Therapeutics Inc has announced that Pfizer expects a pivotal readout in the Phase 3 Affine trial evaluating Giroctocogene Fitelparvovec in the middle of 2024, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 8:10 pm

SRRK

Scholar Rock has presented new data from its Phase 1 DRAGON trial, showing anti-tumor activity in anti-PD-1 resistant metastatic ccRCC patients. The data supports the continued tolerability of SRK-181 and shows a disease control rate of 57% and an objective response rate of 21.4%. The company will discuss the SRK-181 program during a conference call on its Q3 2023 financial results and business updates.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 8:01 pm

KA

Kineta, Inc. (NASDAQ:KA) presented new preclinical data on its lead anti-CD27 monoclonal antibody at the Society for Immunotherapy of Cancer's 38th Annual Meeting. The data showed high binding affinity and specificity, strong T cell activation and proliferation, and NK cell activation. The antibody demonstrated in vivo antitumor efficacy as a single agent and in combination with other immunotherapies in multiple solid and hematological mouse tumor models.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 8:01 pm

AAPL

DIS

The 2023 Rock & Roll Hall of Fame Induction Ceremony will be streamed live on Walt Disney Company's Disney+ and Apple Inc's Apple Music. The event will remain available to stream following the ceremony. The inductees include Kate Bush, Missy Elliott, George Michael, Sheryl Crow, Rage Against the Machine, The Spinners and Willie Nelson.

Portfolio Pulse from Maureen Meehan

November 03, 2023 | 7:49 pm

ARMK

ETN

HCA

PLTR

Palantir Technologies Inc. (NYSE:PLTR) CEO Alex Karp expressed confidence in the company's Artificial Intelligence Platform (AIP) and U.S. commercial during the recent earnings call. The company's AIP has tripled its user base in five months and has 300 distinct organizations signed up, including Tampa General, HCA Healthcare Inc (NYSE:HCA), Cleveland Clinic, Aramark (NYSE:ARMK), Panasonic North America, Eaton Corp PLC (NYSE:ETN), and Carrefour Brazil. Palantir also expects its U.S. commercial segment to grow over 10% YoY.

Portfolio Pulse from Surbhi Jain

November 03, 2023 | 7:25 pm